A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

Inclusion Criteria:

- Healthy term 2-month-old infants for whom a parent/legal representative has given
written informed consent.

Exclusion Criteria:

- Subjects with a previous or suspected disease caused by Neisseria meningitidis,
Corynebacterium diphtheriae, Clostridium tetani, Poliovirus, Hepatitis B, Haemophilus
influenzae type b (Hib), Pneumococcus or Bordetella pertussis; previous immunization
with a meningococcal vaccine or vaccine containing meningococcal antigen(s) or prior
vaccination with Diptheria, Tetanus, Pertussis (acellular or whole cell), inactivated
polio vaccineIPV or oral polio vaccineOPV, H. influenzae type b (Hib) or Pneumococcus;
who have had household contact with and/or intimate exposure to an individual with
laboratory confirmed N. meningitidis (serogroups A, C, W-135, or Y), B. pertussis,
Hib, C. diphtheriae, Polio, or pneumococcal infection at any time since birth; Any
serious acute, chronic or progressive disease